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ABSTRACT
Introduction: Oral daclatasvir (DCV;
pangenotypic NS5A inhibitor) plus asunaprevir
(ASV; NS3 protease inhibitor) is approved in
Japan and Korea for treatment of chronic
hepatitis C virus (HCV) genotype 1. Response
to DCV ? ASV is affected by DCV resistance-
associated polymorphisms (RAPs) in HCV NS5A.
The prevalence and influence of these RAPs on
12-week sustained virologic response (SVR12) to
DCV ? ASV was evaluated in Asian and non-
Asian patients.
Methods: Data were pooled from 5 national
and international studies of patients with HCV
genotype 1b (GT-1b) receiving DCV ? ASV at
their recommended doses. Baseline NS5A RAPs
and their effect on SVR12 were assessed overall,
in older (C65 years) patients, patients with
cirrhosis, and in patients stratified by baseline
HCV RNA or prior treatment experience with
interferon-based therapy.
Results: Baseline NS5A sequences were
available from 988 patients (374 Japanese; 125
Korean/Taiwanese; 489 from non-Asian
countries), 979 of whom were assessed for
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SVR12. Pretreatment NS5A-L31F/I/M/V and/or
NS5A-Y93H polymorphisms were present in
18% of Japanese and 12–13% of non-Japanese
patients; these RAPs reduced SVR12 by 54.9%
overall (93.9% [787/838] SVR12 when absent,
39.0% [55/141] SVR12 when present), with
comparable reductions observed in Asians and
non-Asians and across all categories of
treatment experience, age, and cirrhosis. RAP-
associated SVR12 rates declined with increasing
baseline HCV RNA (SVR12 with RAPs: 64.7%
[11/17] at 5-6 log10 IU/mL, 29.8% [14/47] at 7–8
log10). Without baseline RAPs, very high SVR12
rates (92–100%) were observed in older patients
and patients with cirrhosis irrespective of
national origin, with similarly high rates
observed among treatment-naı¨ve and
interferon-experienced patients and those with
high baseline HCV RNA.
Conclusions: Following DCV ? ASV treatment,
the SVR12 rates in GT-1b patients without
baseline NS5A-L31F/I/M/V and/or NS5A-Y93H
polymorphisms were very high (approximately
90–100%), irrespective of age, cirrhosis, prior
interferon treatment, or baseline HCV RNA.
Funding: Bristol-Myers Squibb.
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INTRODUCTION
Hepatitis C virus (HCV) is a highly polymorphic
single-stranded RNA flavivirus that exists as 7
geographically diverse major genotypes with at
least 67 subtypes [1]. Approximately, 80% of
acute infections with HCV fail to clear
spontaneously and progress to a state of
chronic infection with serious long-term
sequelae. It is estimated that within 20 years of
infection, 60–70% of people with untreated
chronic HCV infection will develop hepatic
steatosis or fibrosis, up to 20% will develop
cirrhosis, and up to 5% will progress to
hepatocellular carcinoma [2]. Chronic HCV
infection is estimated to be responsible for up
to half a million liver-related deaths per annum
[3].
Treatment of HCV has evolved and
improved remarkably in recent years. The
ongoing introduction of all-oral combination
regimens of direct-acting antiviral (DAA) agents
has resulted in significantly shorter treatment
durations, better tolerability, and higher rates of
post-treatment sustained virologic response
(SVR), a surrogate of cure, than earlier
treatments based on the use of parenteral
interferons. One such all-oral regimen
combines daclatasvir (DCV)—a pangenotypic
inhibitor of the multifunctional HCV NS5A
nonstructural protein that is active in vitro
against HCV genotype 1 (GT-1) through GT-6
[4]—with asunaprevir (ASV), an NS3 protease
inhibitor with in vitro activity against HCV GT-
1, GT-4, GT-5, and GT-6 [5]. In combination,
treatment with these two agents has produced
high rates of SVR among patients infected with
the GT-1b subtype, including treatment-naı¨ve
patients, patients medically ineligible for—or
intolerant of—peginterferon alfa and ribavirin
(pegIFN/RBV), and patients who had previously
not responded to or relapsed on pegIFN/RBV
treatment [6–10]. The combination of DCV and
ASV has been approved in Japan and Korea for
the treatment of HCV genotype GT-1 and is
currently under regulatory evaluation in other
countries.
The HCV pandemic in Asia differs from that
in the West in several ways that may impact
response to DCV ? ASV or other new
combinations of DAAs. Across much of Asia,
the GT-1b subtype of GT-1 is the predominant
HCV strain, whereas in North America and
Northern Europe GT-1a is by far the most
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common [2]. The spread of HCV in Asia also
predates that in North America and Western
Europe, resulting in a significantly higher
proportion of elderly patients in countries
such as Japan and Taiwan than in most non-
Asian countries, and a correspondingly higher
incidence of cirrhosis and hepatocellular
carcinoma [11]. Both older age and cirrhosis
are historically associated with a higher burden
of adverse events and poorer responses to
interferon-based therapy [12, 13], and their
influence on response to newer oral regimens
remains an area of great interest and research.
Treatment-emergent NS5A variants
associated with drug resistance and virologic
failure have been described for DCV and other
inhibitors of HCV NS5A, and these may exist
pretreatment as naturally occurring resistance-
associated polymorphisms (RAPs) whose
prevalence may vary by region and subtype.
Treatment-emergent variants at NS5A amino
acid positions 31 and 93 have been observed in
both GT-1a and GT-1b virologic failures
receiving DCV-containing regimens [14–17].
NS5A variants at these amino acid positions
can also exist pre-therapy. In HCV GT-1b-
infected Japanese patients, pre-existence of
NS5A RAPs at L31 or Y93H, as determined by a
population-based direct sequencing approach,
has impacted SVR to DCV ? ASV [17]. Two
additional treatment-emergent NS5A variants
at amino acid positions 28 and 30 have also
been observed in patients with GT-1a virologic
failure receiving DCV-containing regimens,
which may also be present as RAPs at pre-
therapy baseline [14, 15].
Effective use of DCV ? ASV as a treatment
option in Asia requires an understanding of
how RAPs and other influences of importance
to Asian populations, such as older age and
cirrhosis, affect treatment outcomes. The
prevalence of pre-therapy NS5A
polymorphisms, their influence on SVR to
DCV ? ASV treatment, and their interactions
with other potential baseline predictors of
response in both Asian and Non-Asian patients
was evaluated in pooled data from the
DCV ? ASV clinical development program.
METHODS
Studies and Patients
Data were pooled from all 5 phase 2 and phase 3
clinical studies of DCV ? ASV in patients with
chronic HCV GT-1 infection undertaken as part
of the DCV ? ASV development program. The
studies included have all been previously
reported and comprised: AI447-017 (Clinical
Trials.gov number, NCT01012895; phase 2) [7]
and AI447-026 (ClinicalTrials.gov number,
NCT01497834; phase 3) [8] evaluating
DCV ? ASV in Japanese patients with prior
non-response to pegIFN/RBV, or who were
intolerant of or medically ineligible for
pegIFN/RBV; AI447-028 (HALLMARK-DUAL;
ClinicalTrials.gov number, NCT01581203) [9],
a multinational (excluding Japan) phase 3
evaluation of DCV ? ASV in patients who were
treatment-naı¨ve, were prior non-responders to
pegIFN/RBV, or were intolerant/ineligible for
pegIFN/RBV; and AI447-031 (ClinicalTrials.gov
number, NCT01718145) [10], a Japanese phase
3 study of DCV ? ASV in patients who were
treatment-naı¨ve or who had previously
undergone virologic relapse following pegIFN/
RBV treatment. In addition, a subset of patients
were included who received DCV ? ASV in
study AI447-011 (ClinicalTrials.gov number,
NCT01012895) [6], a phase 2 evaluation of
DCV ? ASV, DCV ? ASV ? pegIFN/RBV, and
DCV ? ASV ? RBV in prior non-responders to
pegIFN/RBV from France, Puerto Rico, and the
United States.
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Patients included in these analyses were
infected with HCV subtype GT-1b only and
had been assigned to receive 24 weeks of
DCV ? ASV at their recommended doses of
60 mg DCV once daily with either 200 mg
(phase 2 dry tablet formulation) or 100 mg
(phase 3 soft-gel formulation) ASV twice daily.
Patients had at least 12 weeks of post-treatment
follow-up. Patients with compensated cirrhosis
who fulfilled the other criteria were included
from the 2 studies (AI447-026 and AI447-028)
that enrolled cirrhotic subjects. Cirrhosis was
defined by pretreatment biopsy, or by either a
baseline FibroScan result C14.6 kPa in AI447-
028 or according to the published laboratory
algorithm of Ikeda et al. [18] in AI447-026.
Evaluations and Analyses
Baseline polymorphisms in HCV NS5A present in
approximately 20% or more of the patients’ virus
population were assessed in each study by
population-based sequencing as previously
described [17] using the Con1 GT-1b consensus
sequence as a reference (Accession number:
AJ238799). Briefly, PCR-amplified NS5A
sequences were cloned using a TOPO-TA
Cloning Kit (Invitrogen, Carlsbad, CA, USA) and
sequenced using the BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems,
South San Francisco, CA, USA). Individual
reactions were purified using the BigDye
XTerminator Purification Kit (Applied
Biosystems) before being loaded on an Applied
Biosystems DNA Analyzer 3730XL. Nonconsensus
changes at amino acid positions 28 (L28M), 30
(R30Q), 31 (L31F/I/M/V), and 93 (Y93H) known
to be associated with resistance-associated GT-1
virologic failures on DCV were included in
analyses of prevalence and virologic outcome.
The primary virologic outcome for these
analyses was SVR at post-treatment week 12
(SVR12), which was assessed centrally in each
study and defined as HCV RNA below the lower
limit of assay quantitation (LLOQ) for the assay
used in that study, with or without detectable
target. Japanese studies AI447-017, AI447-026,
and AI447-031 measured HCV RNA using the
Roche COBAS TaqMan HCV Auto assay (Roche
Diagnostics KK, Tokyo, Japan) with an LLOQ of
15 IU/mL. The non-Japanese studies AI447-011
and AI447-028 used the COBAS TaqMan HCV
test version 2.0 (Roche Molecular Systems,
Pleasanton, CA, USA) with an LLOQ of 25 IU/
mL. Missing virologic data at post-treatment
week 12 (i.e., patient missing SVR12 outcome)
was imputed from the next available post-
treatment HCV RNA measurement via a next-
observation-carried-backward approach. Late
relapsers (\LLOQ at post-treatment week 12
but subsequently CLLOQ at a later post-
treatment measurement) were classed as
having had SVR12 failure.
Two populations were derived for the
analyses. The full population comprised all
patients in the 5 studies who had available
baseline NS5A sequence data and is the set in
which the prevalence of baseline NS5A
polymorphisms was assessed. The SVR12
population comprised a subset of the full
population that excluded patients with non-
virologic treatment failures and is the set in
which the effects of polymorphisms and other
baseline factors on SVR12 was assessed. Patients
with non-virologic failure had achieved an SVR
at post-treatment week 4 but had no subsequent
follow-up data, or had received fewer than
84 days (12 weeks) of DCV ? ASV treatment
and discontinued for reasons other than lack
of efficacy.
For both prevalence and SVR12 analyses,
patients were categorized by country of
residence and grouped as ‘‘Japanese,’’ ‘‘Korean/
Taiwanese,’’ and from ‘‘Non-Asian countries.’’
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Three studies (AI447-017, AI447-026, and
AI447-031) were specific to Japan, making
Japanese patients the single largest Asian
group. Smaller numbers of Asian patients from
Korea and Taiwan were enrolled into AI447-
028, which did not enroll patients in Japan, and
were pooled for analysis as a separate Asian
group. The ‘‘Non-Asian countries’’ group
consisted of all others from AI447-028 and
AI447-011 and comprised patients from
Argentina, Australia, Austria, Canada, France,
Germany, Ireland, Israel, Italy, the Netherlands,
Poland, Russia, Spain, the United Kingdom, and
the United States. Patients were further
stratified for SVR12 analysis by prior treatment
status, cirrhosis status, age, baseline HCV RNA,
and the presence of NS5A polymorphisms at
L31 and Y93H.
All analyses were descriptive, without formal
significance testing. The analyses described are
based on data from earlier studies, described
elsewhere, that were conducted in accordance
with all relevant national and local ethical and
regulatory requirements and in accordance with
the Helsinki Declaration of 1964 and its
subsequent revisions. No new studies of
human or animal subjects were performed for
these analyses.
RESULTS
Patient Demographics
Table 1 summarizes the 5 studies included in
these pooled analyses and the number of
patients from each who were included in the
assessments of NS5A polymorphisms and
SVR12 outcomes. In total, 988 patients were
included in the full population, of whom 979
formed the SVR12 population. The 9 patients
in the full population who were excluded from
the SVR12 population comprised 2 patients
(studies AI447-017 and AI447-028) who did
not meet study criteria for resistance testing at
failure due to having HCV RNA\LLOQ at their
last visits; 2 patients (studies AI447-026 and
AI447-028) who had requested that treatment
be discontinued; 2 patients in AI447-028 who
withdrew consent; 1 patient in AI447-028 who
was lost to follow-up; and 2 patients in AI447-
026 who discontinued therapy due to an
adverse event.
Table 1 Studies included in the pooled analyses
Study ClinicalTrials.
gov ID
Phase Patients Analyzed
for
BL NS5A
Analyzed
for
SVR12
References
AI447-011 NCT01012895 2 Non-respondersa 17 17 Lok et al. [6]
AI447-017b NCT01051414 2 Non-respondersa or IFN/RBV
intolerant or ineligible
33 32 Suzuki et al. [7]
AI447-026b NCT01497834 3 Non-responders or IFN/RBV
intolerant or ineligible
214 211 Kumada et al. [8]
AI447-028 NCT01581203 3 Naı¨ve, non-responders, or IFN/
RBV intolerant or ineligible
597 592 Manns et al. [9]
AI447-031b NCT01718145 3 Naı¨ve and IFN relapsers 127 127 Chayama et al. [10]
BL baseline, IFN interferon, RBV ribavirin
a All enrolled in this category were null responders
b Japan-only studies
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The full population (Table 2) comprised 296
treatment-naı¨ve patients, 304 non-responders
to pegIFN/RBV, 371 patients unable to be
treated with pegIFN/RBV for reasons of
intolerance or medical ineligibility, and 17
prior relapsers on pegIFN/RBV. There were 374
Japanese patients (37.9% of total), 63 Koreans
(6.4%), 62 Taiwanese (6.3%), and 489 patients
(49.5%) from non-Asian countries.
Prevalence of NS5A Polymorphisms
The prevalence of NS5A baseline
polymorphisms in the full population is
shown in Fig. 1. With the exception of amino
acid 31, polymorphisms at the positions of
interest generally appeared to be more
common among Asian than non-Asian
patients. In particular, the incidence of NS5A-
Y93H with or without L31F/I/M/V
polymorphisms was higher among Japanese
patients than among Koreans, Taiwanese, or
patients from non-Asian countries. When
stratified by age, the incidence of Y93H
remained higher among both younger and
older Japanese patients than among the other
Asians and non-Asians: 13.6% (34/250) in
Japanese patients\65 years old and 17.7% (22/
124) in Japanese patients C65 years, versus 9.6%
(9/94) and 12.9% (4/31), respectively, among
Koreans and Taiwanese, and 7.4% (30/403) and
5.8% (5/86), respectively, among non-Asians.
The prevalence of Y93H was higher in older
than in younger Asian patients (overall 16.8%
[26/155] in Japanese, Koreans and Taiwanese
C65 years old, versus 12.5% [43/344] in those
Table 2 Baseline characteristics
Characteristic Treatment naı¨ve
(N5 296)
Non-responders
(N5 304)
IFN/RBV intolerant or
ineligible (N5 371)
Relapsers (N5 17)
Age
Mean (range), years 53.4 (20–79) 56.7 (23–77) 59.4 (24–77) 61.4 (45–75)
\65 years, n (%) 254 (85.8) 235 (77.3) 248 (66.8) 10 (58.8)
C65 years, n (%) 42 (14.2) 69 (22.7) 123 (33.2) 7 (41.2)
Male, n (%) 138 (46.6) 159 (52.3) 140 (37.7) 7 (41.2)
Countries, n (%)
Japan 110 (37.2) 97 (31.9) 150 (40.4) 17 (100)
Korea 21 (7.1) 20 (6.6) 22 (5.9) 0
Taiwan 19 (6.4) 21 (6.9) 22 (5.9) 0
Non-Asian 146 (49.3) 166 (54.6) 177 (47.7) 0
HCV RNA
Mean (range), log10 IU/mL 6.5 (4.0–8.0) 6.6 (4.0–8.0) 6.4 (4.0–8.0) 7.1 (6.0–8.0)
Cirrhotic patients, n (%) 31 (10.5) 71 (23.4) 115 (31.0) 0
Baseline NS5A polymorphisms, n (%)
L31F/I/M/V 13 (4.4) 18 (5.9) 11 (3.0) 1 (5.9)
Y93H 26 (8.8) 25 (8.2) 52 (14.0) 1 (5.9)
HCV hepatitis C virus, IFN interferon, RBV ribavirin
642 Adv Ther (2015) 32:637–649
under 65 years), whereas the prevalence in older
non-Asians (5.8%) was similar to or slightly
lower than that in younger patients (7.4%).
Effect of NS5A Polymorphisms and Other
Baseline Factors on SVR12
The association between baseline NS5A
polymorphisms and SVR12 is shown in Fig. 2
for the full SVR12 population of 979 patients.
Among all GT-1b-infected patients, the
presence of the DCV NS5A RAPs L31F/I/M/V
and/or Y93H at baseline was associated with
reduced SVR12 following treatment with
DCV ? ASV (SVR12 range: 36.9–41.9%), while
SVR12 rates in the absence of these RAPs were
high (SVR12 range: 88.0–93.9%). By contrast,
neither baseline L28 M nor R30Q had any
Fig. 1 Prevalence of baseline NS5A polymorphisms in Hepatitis C virus genotype 1b
Fig. 2 SVR12 with versus without baseline NS5A polymorphisms. SVR12 12-week sustained virologic response
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relevant effect on SVR12 in the absence of NS5A
polymorphisms at amino acids 31 or 93 (SVR12
approximately 86%).
In contrast to the presence of NS5A-L31F/I/
M/V or NS5A-Y93H, prior treatment status,
older age (C65 years), and the presence of
compensated cirrhosis did not influence
SVR12 in either Asian or non-Asian patients.
Figure 3 shows SVR12 by prior treatment status
and presence of NS5A RAPs, and Fig. 4 shows
SVR12 by age, cirrhosis status, and presence of
NS5A RAPs for each national grouping. In the
absence of baseline NS5A RAPs, SVR12 rates
ranged from 89% to 100% across prior
treatment categories, and were above 90%
irrespective of age or cirrhosis. There was no
evidence of a difference in SVR12 outcomes
between Japanese, non-Japanese Asians and
patients from non-Asian countries. The
declines in SVR12 among those with baseline
NS5A RAPs versus those without were broadly
similar across each baseline category, with no
evidence of an interaction.
Figure 5 shows SVR12 by categories of
baseline HCV RNA from\5 log10 to 7–8 log10
IU/mL and the presence of NS5A RAPs for all
979 patients in the SVR12 population. SVR12
rates declined with increasing viral load, with a
slight reduction among patients without
baseline NS5A RAPs, and a more substantial
reduction among those with baseline L31 or
Y93H polymorphisms.
Fig. 3 SVR12 by prior treatment status and presence of baseline NS5A polymorphisms. IFN Interferon, SVR12 12-week
sustained virologic response
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Fig. 4 SVR12 by age, cirrhosis status, and presence of baseline NS5A polymorphisms. SVR12 12-week sustained virologic
response
Fig. 5 SVR12 by baseline HCV RNA and presence of baseline NS5A polymorphisms. HCV Hepatitis C virus, SVR12
12-week sustained virologic response
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DISCUSSION
Pretreatment polymorphisms at NS5A amino
acid positions 31 or 93 in HCV GT-1b have been
previously shown by Karino et al. [17] to reduce
SVR to DCV ? ASV by approximately 50% in a
small sample of Japanese patients in study
AI447-017. These findings were confirmed in
this large, pooled dataset of patients including
study AI447-017 and 4 additional studies, with
the pre-existence of L31F/I/M/V or Y93H at
baseline resulting in an overall 55% reduction
in SVR12, from 94% to 39%. These data also
established a higher prevalence of L31 or Y93H
polymorphisms in the Japanese GT-1b
population (18%) than in the non-Japanese
patients (12–13%). This difference was driven
by the prevalence of Y93H, which was twice as
common among Japanese patients (15%) than
those from non-Asian countries (7%), and 50%
more common than among Asian patients from
Korea and Taiwan (10%). The difference in
Y93H prevalence between Japanese and other
Asian patients was primarily due to a higher
prevalence in Japanese patients under 65 years
old than in younger Koreans and Taiwanese
(13.6% versus 9.6%), but with an additional
contribution from the higher proportion of
older (C65 years) patients in the Japanese
group (33%) compared to the non-Japanese
Asians (25%) amongst whom the prevalence of
Y93H was also higher (17.7% in older Japanese
versus 12.9% in older Koreans and Taiwanese).
Interestingly, baseline polymorphisms at
NS5A amino acid positions 28 or 30,
previously associated with GT-1a virologic
failures to DCV, were also twice as prevalent
in both GT-1b Japanese and non-Japanese
Asians (12%) compared with non-Asians (6%).
However, these polymorphisms had no effect
on SVR12 outcomes and therefore cannot be
considered RAPs for GT-1b.
Among the key baseline characteristics of
age, cirrhosis status, prior pegIFN/RBV
treatment experience, and the presence of
NS5A RAPs at L31 and Y93H, only the NS5A
RAPs reduced SVR12. In the absence of L31F/I/
M/V or Y93H, very high SVR12 rates, typically
between 90% and 100%, were observed for all
categories and with no obvious differences
between Asian and non-Asian patient groups.
Indeed, among those without baseline NS5A
RAPs, 99% of elderly Japanese patients and
100% of Japanese patients with cirrhosis
achieved SVR12 following DCV ? ASV
treatment, along with similarly high
proportions (92–96%) of elderly and cirrhotic
patients without RAPs from Korea and Taiwan
or from the non-Asian countries.
The only baseline characteristic examined
that had an effect on SVR12 independent of
baseline NS5A RAPs was HCV RNA, where a
small but continuous decline in SVR12 from
100% to 91% was evident across baseline strata
ranging from\5 log10 IU/mL to 7–8 log10 IU/
mL. This was also the only baseline
characteristic that appeared to show an
interaction with the presence of NS5A RAPs.
In the absence of NS5A RAPs, a reduction in
SVR12 rate of only 9% across all RNA strata was
observed; however, in the presence of NS5A
RAPs, reductions in SVR12 of approximately
50% were observed, with SVR12 rates ranging
from 65% with a baseline viremia of 5–6 logs to
30% with 7–8 logs. The data suggest that the
effects of NS5A-L31 and NS5A-Y93H
polymorphisms on response to DCV ? ASV are
partially mitigated by low baseline viremia.
It is relevant to note that reduced baseline
susceptibility to DCV may also be mitigated by
the composition of the DCV-containing
regimen. Reduced HCV susceptibility at
baseline to any given antiviral may in
principle be compensated using that antiviral
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in combination with several non-cross-resistant
agents, and/or in combination with potent
agents with a high barrier to resistance. The
significant predictive effect of NS5A L31 and
Y93H RAPs on reduced response to DCV ? ASV
shown here and in the data from Karino et al.
[17] has not been apparent where DCV ? ASV is
used in combination with the non-nucleoside
NS5B-inhibitor beclabuvir (BCV), or in studies
of DCV with the nucleotide NS5B-inhibitor
sofosbuvir. In the UNITY-1 (ClinicalTrials.gov
number, NCT01979939) [19] and UNITY-2
(ClinicalTrials.gov number, NCT01973049)
[20] studies of 12 weeks of treatment with
DCV ? ASV ? BCV for GT-1 infection in
patients without (UNITY-1) or with (UNITY-2)
compensated cirrhosis, SVR12 was achieved by
100% of GT-1b-infected patients in both studies
who had baseline NS5A RAPs at positions 28,
30, 31, or 93 (17 in UNITY-1, 13 in UNITY 2). In
comparison, SVR12 among GT-1a-infected
patients with baseline RAPs at these positions
was 74% [25/34] in UNITY-1 and 87% [13/15] in
UNITY-2. Similarly, in study AI444-040
evaluating DCV plus sofosbuvir with or
without ribavirin, only 1 patient among 28
with GT-1, GT-2, or GT-3 infection and baseline
NS5A-L31M or NS5A-Y93H/C/N failed to
achieve SVR12, and this patient achieved SVR4
before being lost to follow-up [21]. These
clinical data are consistent with in vitro
observations of the antiviral activity of DCV
plus sofosbuvir or DCV ? ASV ? BCV in DCV
and ASV-resistant GT-1b subgenomic replicon
cell lines bearing NS5A-L31M, NS5A-Y93H and
NS3-D168V variants [22]. Thus, the clinical
relevance of any given RAP or combination of
RAPs on HCV response to a given DAA regimen
cannot necessarily be extrapolated to other
combinations involving the affected drugs.
While there are many baseline factors that
could influence sustained HCV responses to a
given regimen, overall these data suggest that
pre-therapy screening for NS5A polymorphisms
at L31 and Y93H may be beneficial in patients
with HCV GT-1b infection eligible for treatment
with DCV ? ASV. Although this was a
descriptive study without formal statistical
testing, very high response rates to DCV ? ASV
of 90–100% were observed for patients where
these NS5A polymorphisms were not detected
by population-based sequencing, while patients
with these NS5A polymorphisms were less likely
to respond to this combination and may
therefore obtain greater benefit from a
different DCV-based combination. As discussed
above, there are clinical data to suggest that GT-
1b-infected patients with baseline NS5A
polymorphisms at L31 or Y93H will respond
well to DCV plus sofosbuvir [21], or
DCV ? ASV ? BCV [19, 20]. There appears to
be an ameliorating effect of low baseline HCV
RNA on the influence of baseline NS5A
polymorphisms at L31 and/or Y93H on
sustained response to DCV ? ASV, but it is a
limitation of the study that the number of
patients with low HCV RNA and these
polymorphisms is too low to establish a robust
threshold of effect for clinical decision making.
CONCLUSIONS
Pooled data from clinical studies of DCV? ASV
for chronic HCV GT-1b infection show that the
most significant baseline correlate of SVR so far
observed is the presence of pre-therapy DCV RAPs
at NS5A amino acids L31 and/or Y93H. In the
absence of these NS5A RAPs, very high rates of
SVR12, between 90% and 100%, were achieved,
irrespective of older age, cirrhosis, prior
experience of pegIFN/RBV, or baseline HCV RNA
level. These data are of relevance to physicians in
Asian countries where DCV? ASV is approved for
HCV treatment.
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